All patients had EGFR 20ins documented by local testing at enrollment, 143 of whom (95.3%) were further confirmed by central testing on tumor tissue samples (n = 143) and/or paired peripheral blood samples (n = 117). The gene discussed is EGFR; the disease is neoplasm.